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INTRODUCTION
Achieving curative gene therapy for genetic diseases has been a 
remarkable reward after 30 years of bench-to-bedside transfer.1 We 
now foresee the advent of a medical revolution with cellular repro-
gramming and genome editing, alone or in combination.1 In the cell 
and gene therapy era, the need for improved targeted expression of 
cellular factors is critical.2,3 Moreover, for biological and safety rea-
sons, the lifelong persistence of foreign genetic information is not 
desirable in many cases.4 Protein delivery has recently allowed tran-
sient expression in various cell types.5,6 RNA transfer also remains 
relevant and has been extensively developed with chemical, viral, 
and biophysical techniques. Importantly, RNA transfer allows tran-
sient expression and tuneable control.7
By exploiting the mRNA nature of the retroviral genome,8 Baum 
and others converted murine oncoretroviruses into RNA transfer 
vectors,9–11 which was then extended to other retroviruses.12,13 
mRNA delivery from retroviral vectors involved the natural Ψ 
sequence and knockdown of molecular determinants for reverse 
transcription, or modification of cellular mRNA by adding the 
retroviral packaging sequence.10,14 Hence, these platforms fea-
ture viral constraints in genome recruitment and the use of the 
canonical viral-packaging sequence restrains delivery to no more 
than two RNAs per particle.8 An alternative packaging system not 
relying on the dimerization of the genomic RNA could improve 
the efficiency of transduction.
To improve RNA transfer by retroviral platforms, we designed 
novel chimeric particles that rely on the well-characterized interac-
tion between bacteriophage MS2-Coat protein and the MS2-RNA 
genome.15 Through the physiological recognition of its cognate 
RNA, MS2-Coat governs the replication-to-assembly transition dur-
ing the leviviridae lytic cycle.16 This interaction involves a 19-nt stem-
loop structure within the phage replicase gene.17 MS2-Coat protein 
systems have wide application for studying RNA biology and fluo-
rescent MS2-Coat-protein have been used to track cellular RNAs.18,19 
Recently, MS2-Coat was used for semisynthetic gene delivery.20,21 
Here, we challenged retroviral plasticity to tolerate insertion of an 
MS2-Coat domain allowing for heterogeneous RNA recruitment.6 
Several retroviral sequences were amenable to modification in ret-
roviral-based vectors.6,22 In this study, we evaluated the capacity to 
transfer MS2-Coat-binding RNAs from our redesigned HIV-1-derived 
vectors. Having shown particle formation, and confirmed by quan-
titative assays that MS2 chimeric RNA lentiviral particles (MS2RLPs) 
contained significantly more than two RNAs, we achieved visible 
efficient transfer of functional RNAs in vitro, with no need for selec-
tion. Concentrated chimeric particles led to significant liver and 
muscle transduction in vivo. Finally, lentiviral cargoes containing 
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RNA delivery is an attractive strategy to achieve transient gene expression in research projects and in cell- or gene-based therapies. 
Despite significant efforts investigating vector-directed RNA transfer, there is still a requirement for better efficiency of delivery 
to primary cells and in vivo. Retroviral platforms drive RNA delivery, yet retrovirus RNA-packaging constraints limit gene transfer 
to two genome-molecules per viral particle. To improve retroviral transfer, we designed a dimerization-independent MS2-driven 
RNA packaging system using MS2-Coat-retrovirus chimeras. The engineered chimeric particles promoted effective packaging of 
several types of RNAs and enabled efficient transfer of biologically active RNAs in various cell types, including human CD34+ and 
iPS cells. Systemic injection of high-titer particles led to gene expression in mouse liver and transferring Cre-recombinase mRNA in 
muscle permitted widespread editing at the ROSA26 locus. We could further show that the VLPs were able to activate an osteoblast 
differentiation pathway by delivering RUNX2- or DLX5-mRNA into primary human bone-marrow mesenchymal-stem cells. Thus, 
the novel chimeric MS2-lentiviral particles are a versatile tool for a wide range of applications including cellular-programming or 
genome-editing.
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mRNAs coding osteogenic transcription factors triggered a shift in 
the transcription program of primary bone-marrow mesenchymal 
stem cells (MSCs).
ReSUlTS
Chimeric MS2-Coat-lentiviral particles promote efficient packaging 
of MS2-RNA
To date, because the natural mode of packaging implies RNA dimer-
ization within Ψ, the number of RNAs within each particle is limited to 
2.8,23 To increase retroviral mRNA delivery, we engineered dimeriza-
tion-independent RNA recruitment by exploiting the specific inter-
action between the phage MS2-Coat protein and MS2 RNA genome 
in a lentiviral context. For this, we needed to design two compo-
nents, the biologically active RNA to be recruited and the recruiting 
particle. The minimal 19-nt stem-loop sequence required for interac-
tion between the phage MS2-Coat protein and MS2 RNA was intro-
duced in multiple copies24,25 into a eukaryotic expression vector. We 
first cloned the stem-loop at the 3’ end of a reporter gene, luciferase 
(Luc_MS2_12X) (Figure 1a). Next, to obtain the packaging of MS2-
stem-loop containing RNA into a particle, we engineered an HIV-1-
based complementation vector.26 HIV-1 recruits its genomic RNA via 
a complex process,8,23 in which the viral nucleocapsid protein (NC) 
has a central role. Because NC has several other functions in HIV-1 
biology, we could not simply replace it (for review, see ref. 27). HIV-1 
NC contains two zinc finger domains (ZF1 and ZF2) involved in RNA 
interaction; ZF2 was shown to be dispensable for particle budding22 
and was thus selected for modification. We first generated a refer-
ence and negative control construct (p8.74 ΔZF, Figure 1a) and next 
introduced in-frame the sequence encoding bacteriophage MS2-
Coat protein, replacing ZF2 (p8.74 ΔZF_MS2-coat) (Figure 1a).
To determine whether this system could allow MS2-lentiviral par-
ticle (MS2RLPs) formation and mRNA recruitment, the Luc_MS2_12X 
vector was transfected along with each HIV-1 packaging construct 
(p8.74, p8.74 ΔZF, or p8.74 ΔZF_MS2coat). In the first experiments, 
MS2RLPs were pseudotyped by the 4070A amphotropic envelope, 
preventing unspecific release of cellular vesicles formed by the 
 pantropic VSV-G.28
Measurements of the concentration of CAp24 in the  supernatant 
from control and MS2RLPs transfected cells by enzyme-linked 
immunosorbent assay (ELISA) suggested that the packaging con-
structs supported particle formation (data not shown). This was 
confirmed by electron microscopy showing particles in the medium 
from transfected cells (Figure 1b). Morphologically, the majority of 
MS2RLPs appeared similar to conventional lentiviral vectors with 
only a slight change in shape and size (Figure 1b). Of note, these 
differences were associated with the presence of unprocessed Gag 
precursor in MS2RLPs (Supplementary Figure S1a).
Next, we analyzed uptake of luciferase-mRNA into the MS2RLPs. 
Quantitative reverse transcription polymerase chain reaction 
(RT-qPCR) confirmed the specific recruitment of Luc_MS2_12X 
mRNA into MS2RLPs (Figure 1c, 6 compared to 4 and 5). The paren-
tal construct allowed for packaging the Ψ-containing genome but 
it failed to recruit Luc_MS2_12X mRNA (Figure 1c, 1–2 compared 
to 4). Similarly, the p8.74 ΔZF control vector failed to package Luc_
MS2_12X mRNA (Figure 1c, sample 5), which emphasizes the cru-
cial role of the interaction between MS2-Coat protein and the MS2 
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19-nt stem-loop. Importantly, because the amount of luciferase 
RT-qPCR mRNA was normalized to that of particle load measured by 
CAp24, the higher signal obtained for MS2RLP-Luc suggested that 
MS2RLPs packaged more RNA molecules per particle than the wild-
type Ψ-dependent lentiviral system (Figure 1c, compare sample 1 
and 6). Since MS2RLPs had a shape close to that of regular lentiviral 
vectors (Figure 1b), we hypothesized that the CAp24 concentration 
was proportional to the number of particles released both for the 
standard lentiviral vectors and for MS2RLP. This was confirmed by a 
western blot analysis of MS2RLP and integrative-lentiviral (ILV) parti-
cles showing that both particles contained detectable CAp24, while 
MS2RLP had a higher proportion of Gag precursor (Supplementary 
Figure S1a). To accurately estimate the MS2RLP RNA contents, we 
designed a dilution-based method (see Materials and Methods and 
Supplementary Figure S1b). These results allowed us to show that 
MS2RLP contained around 2.8 times more RNA than a standard 
vector (Supplementary Figure S1b). Considering that Ψ-dependent 
vectors contained two viral genomes, we estimated the number 
of RNA molecules per MS2RLP to be around 5 to 6 (Figure 1c and 
Supplementary Figure S1b).
Kinetic of MS2RLP-delivered RNA expression
We further showed that MS2RLPs drove rapid and efficient gene 
expression in vitro. To assess the functionality of the packaged 
Figure 1 MS2-driven RNA packaging into chimeric MS2-coat lentiviral particles. (a) Vectors for mRNA recruitment into MS2RLP. RNA transfer vector: 
control and reporter constructs. plenti_Luc: lentiviral vector serving as positive control for Ψ-dependent packaging. pLuc: a pcDNA-derived vector 
expressing the luciferase gene. Luc_MS2_12X: model construct designed to evaluate MS2-Coat protein based recruitment, the luciferase gene expressed 
under the CMV promoter contains 12 copies of the 19-nt RNA stem-loop from MS2 bacteriophage (MS2_12X). BGH-pA: Bovine growth hormone poly-
adenylation signal. In red, detail of the sequence for two repeats. Packaging sequence: p8.74 (WT): standard HIV-1 trans-complementation, p8.74 ΔZF 
(ΔZF): derived from WT by deletion of the ZF2 in Nucleocapsid (NC). p8.74 ΔZF-MS2coat (ΔZF_MS2coat): vector containing MS2-Coat protein in place 
of the ZF2. CA, capsid; MA, matrix; MS2-coat, coat protein from MS2 bacteriophage; NC, nucleocapsid; POL, polymerase. (b) Transmission electron 
microscopy. (1) Control integrative lentiviral vectors; (2) MS2RLPs, picture include the smaller and larger particles. Both particles were observed by 
transmission electron microscopy in negative staining conditions using a LaB6 JEOL JEM2100 electron microscope (magnification: ×52,800). Bars 
50 nm. (3) Boxplot, distribution of the average size of particles measured from 52 pictures of integrative-lentiviral (ILV) (dark blue) and 35 of MS2RLP 
(light blue). Images and counts were obtained from a single production of each vector. (c) RT-qPCR analysis of luciferase mRNA level in MS2RLPs. 
Control and MS2RLP samples of DNAse-treated supernatant collected 48 hours after transfection. In all particles collected, no DNA amplification was 
observed without an RT step (data not shown). The analyzed volume was defined after normalization to CAp24 concentration in the supernatant. Data 
are mean ± SD (n = 3, in duplicate). Gag-WT: lentiviral vector expressing a wild-type Gag. Gag-ΔZF: lentiviral vector expressing a ZF2 deleted Gag. Gag-
ΔZF_MS2Coat: lentiviral vector expressing Gag with ZF2 replaced by MS2coat sequence. Env-Ampho: amphotropic envelope. pLenti_Luc: lentiviral 
vector expressing the Luciferase gene. Luc_MS2_12X: mRNA containing 12 repetitions of MS2 RNA stem loop and the Luciferase coding sequence. 
Combination of Gag-ΔZF_MS2Coat, Luc_MS2_12X.
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MS2-12X mRNA, we assayed whether packaged RNAs enabled lucif-
erase expression. Filtered supernatants, harvested 48 and 72 hours 
after transfection, were used to transduce 293T cells. Luciferase 
activity was measured 3 hours after transduction (Figure 2a, dark 
blue bars, samples 1–6). Luciferase expression was detected in cells 
transduced with MS2RLPs, but only at background levels in wild-
type or ΔZF lentiviral control constructs (Figure 2a, dark blue bars; 
4, 5 compared to 6), demonstrating that packaged mRNAs were 
functional. To ensure that the detected luciferase activity was due 
to mRNA transfer and subsequent translation, and not to pseudo-
transduction, the passive transfer of luciferase protein, we pre-
treated recipient 293T cells with 3 µg/ml of the translation inhibitor 
puromycin at 1 hour before transduction (Figure 2a, light blue bars). 
Puromycin-treated cells showed only background luciferase activ-
ity as compared with nontreated cells (Figure 2a, sample 6, dark 
blue versus light blue bars). Therefore, luciferase activity  measured 
in transfected cells resulted from the translation of the transferred 
mRNA. We next compared the kinetics of luciferase expression. 
MS2RLPs carrying the Luc mRNA (MS2RLP-Luc) were used to trans-
duce HCT116 cells and luciferase expression was evaluated 4, 8, 16, 
and 24 hours later (Figure 2b). Control cells were transfected with a 
standard luciferase expression vector (pLuc) or transduced with inte-
gration-defective (IDLV-Luc) or integrative-lentiviral (ILV-Luc) vec-
tors carrying the luciferase gene under the EF1 promoter. MS2RLP-
driven luciferase expression was high and stable from 4 to 24 hours 
(Figures 2b and 3). A rapid decrease occurred in expression after 30 
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hours and was complete at 48 hours (Supplementary Figure S2a). 
Transfection of pLuc conferred detectable luciferase expression 
only after 8 hours and peaked at 24 hours, whereas IDLV or ILV con-
ferred detectable luciferase expression only at 24 hours after trans-
fer (Figure 2b; panels 2, 4, and 5). Therefore, the RNA delivered by 
MS2RLPs was more rapidly expressed than the plasmid-driven gene 
expression, conventional or nonintegrating lentiviral vectors. This 
showed that MS2RLPs allowed for rapid and high gene-expression.
We next evaluated MS2RLP functionality with a green fluores-
cent protein (GFP)-based reporter system using MS2-12X-GFP 
RNA (MS2RLP-GFP). For comparison, MS2RLP and GFP express-
ing IDLV particles were produced and concentrated side by side 
and identical volumes of vector supernatants were used to trans-
duce human hematopoietic cord blood CD34+ cells at several time 
points after thawing (Figure 2c1). For cells transduced several times 
at 12 hours interval, more than 90% of the cells were GFP-positive 
cells with both vectors (Figure 2c1). Interestingly, the proportion 
of  GFP-positive cells was twice higher with MS2RLP-GFP than with 
IDLV-GFP when cells were transduced immediately after thawing 
(Figure 2c1,2c2). This certainly reflected the need for CD34+ cells 
to be activated before efficient transduction.29 MS2RLP-GFP led to 
higher fluorescence intensity at early time points, but it tended to 
decrease slightly more rapidly than for IDLV-GFP (Figure 2c1).
In an effort to compare transduction and expression efficacy 
from MS2RLP-GFP to that obtained with other transfection meth-
ods, we used electroporation, one of the only methods capable of 
allowing efficient transfection of human primary CD34+ cells. For 
this, we used the 4D-Nucleofector technology and an appropriate 
kit from Lonza. In this condition, plasmid transfection gave a high 
rate of GFP-expressing cells with high fluorescence intensity (Figure 
2c3). On the contrary, transfection of a stabilized EGFP mRNA (Trilink 
Biotechnologies) gave rise to almost undetectable level of expression 
(Figure 2c3). In order to confirm that the EGFP mRNA was functional, 
we transfected HEK293T cells with Lipofectamine 2000. More than 
20% of the cells expressed the fluorescent protein at a high level (data 
not shown). This suggested that CD34+ cells were difficult to trans-
fect using synthetic mRNA and the Nucleofector technology. We also 
tried to transfect the EGFP mRNA using the TransIT-mRNA transfec-
tion kit from Mirus Bio, but it failed to efficiently allow GFP expression 
in CD34+ cells (Supplementary Figure S2b). Altogether, these results 
suggested that MS2RLP allowed significant CD34+ hematopoietic 
cells transduction, even in the absence of cell activation by cytokines.
We further evaluated MS2RLP functionality of MS2-12X-tagged 
GFP RLP (MS2RLP-GFP) in cell lines. As for the luciferase, GFP was 
readily detectable, at high efficiency in more than 95% of Hela 
cells transduced with MS2RLP-GFP (Supplementary Figure S2c). 
However, we noticed distinct expression-kinetics, since GFP was 
detected only 24 hours following transduction and for up to 3 
days (Supplementary Figure S2c). This difference could be due to 
the low sensitivity in GFP measurements by fluorescence-activated 
cell sorting (FACS), which would delay detection and to the longer 
half-life of the protein, which conferred prolonged detectability.30 
As expected, the fluorescence decreased overtime and was cleared 
at 7 days post-transduction (Supplementary Figure S2c, lower right 
panel). Lastly, we showed that a single administration of MS2RLPs 
to human induced pluripotent stem cells (iPS) allowed for efficient 
Figure 2 MS2RLP allow efficient RNA expression following mRNA transfer. (a) Luciferase activity after MS2RLP transfer of luciferase-MS2 mRNA into 293T cells. 
293T cells without (dark blue) or pretreated with 3 µg/ml puromycin (light blue) were transduced with 100 µl crude supernatant from MS2RLPs containing 
luciferase mRNA (MS2RLP-Luc) and controls harvested 48 hours post-transfection. At 3 hours post-transduction, cells were extensively washed, lysed, and 
luciferase activity was measured. Plotted results were obtained after normalization to CAp24 antigen except for sample 3 and 7 for which a representative 
extraction aliquot was studied. NS, not significant; (* < 0.05); (** < 0.01), and (*** < 0.001) by Wilcoxon-Mann-Whitney test. (b) Kinetics of luciferase activity 
upon MS2RLP transfer into HCT116 cells. HCT116 cells were transduced with MS2RLP-Luc, integrase-deficient lentiviral vector expressing luciferase (IDLV-Luc); 
20 pg of CAp24/cell in both cases. Controls were an integrative lentiviral vector expressing luciferase (ILV-Luc), 0.57 pg CAp24/cell and the transfection of a 
recombinant luciferase expression plasmid (pLuc). Cells were washed and lysed, and luciferase activity was measured at various times post-transduction or 
transfection (see legend). NT, nontransfected or nontransduced cells. (c1 and c2) Green fluorescent protein (GFP) expression into hematopoietic cells. CD34+ 
cells were thawed, suspended in culture medium at a concentration of 1.5 million cells per ml, and plated in 96-well plates. 200,000 cells were transduced 
with no vector, 13 µl of concentrated IDLV-GFP or 13 µl of concentrated MS2RLP-GFP, in the presence of protamine sulfate (8 µg/ml). Cells were transduced 
once, (right after thawing, top panels), twice (after thawing and 12 hours later, middle panels), or three times (after thawing, 12 and 24 hours later, bottom 
panels). GFP-expressing cells and median fluorescence intensities (MFI) were analyzed by flow cytometry, 36 hours after the last transduction and beyond 
(2c1). Detailed results are given for the one-shot transduction experiment, as measured 36, 48, 72, and 120 hours after transduction (2c2). (c3) 50,000 CD34+ 
cells were transfected either with 0.4 µg of a GFP expressing plasmid (pmaxGFP) or with a GFP mRNA using the 4D-nucleofector X unit 1 day after cell thawing. 
GFP cell expression was analyzed 2 days later by Flow cytometry (BD FACSCanto II, Becton Dickinson) and the Diva software (Becton Dickinson). (d) MS2RLPs 
transfer of Cre recombinase mRNA into HCT116-Lox-dsRed-Lox cells. Polyclonal or clonal HCT116-Lox-dsRed-Lox cells were transduced with 20 pg CAp24/
cell of a IDLV-Cre (samples 3 and 6) or MS2RLP containing Cre recombinase mRNA (MS2RLP-Cre) (samples 4 and 7). At 17 days after transduction, fluorescence 
was measured and quantified by FACS analysis. Sample 1: control normal HCT116 cells. Samples 2 and 5: Untransduced HCT-Lox-dsRed-Lox cells. Data are 
mean ± SD (n = 3). (e) Detection of Cre recombinase DNA sequence in transduced cells. HCT116-Lox-dsRed-Lox cells transduced with MS2RLP-Cre, ILV-Cre, or 
transfected by a plasmid expressing the Cre recombinase, were maintained in culture for 6 (dark blue) to 14 days (light blue). After DNA extraction, a quantitative 
PCR assay allowed for specific Cre recombinase gene detection.
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GFP expression (Supplementary Figure S2d), and that MS2RLPs 
driven RNA-delivery resulted in a dose-dependent GFP signal 
(Supplementary Figure S2d).
MS2RLPs allow efficient gene editing following Cre-mRNA transfer
These results prompted us to evaluate the expression of a protein 
active following its transfer into the nucleus of recipient cells. For 
this purpose, we cloned the Cre recombinase gene in a MS2-12X 
mRNA expression vector and evaluated its efficacy in promoting 
gene excision within cells stably expressing the dsRed protein from 
a floxable transgene (see methods). Following transfer, MS2RLP-Cre 
could induce the stable excision of the dsRed transgene (Figure 2d, 
sample 4 for the polyclonal population and sample 7 for clone 
14). Of note the stability of excision suggested 100% efficacy fol-
lowing MS2RLP transfer. Equivalent excision was observed with an 
IDLV expressing Cre from an EF1 promoter (Figure 2d, sample 3 for 
the polyclonal population and sample 6 for clone 14). Remarkably, 
transfection of a Cre expression plasmid or stable expression of 
the Cre gene with an ILV, were less efficient in promoting excision 
(Supplementary Figure S2e). The fact that the target cells contained 
a mean of 6 floxable transgenes for the cell population and 13 flox-
able sites for the clone, implied that one single MS2RLP-Cre delivery 
was sufficient to excise several loci.
The RNAs packaged into MS2RLP do not contain any retrovi-
ral sequence involved in the reverse transcription process, which 
Figure 3 MS2RLP transfer of HCV subgenomic-replicon RNA. (a) Constructs for MS2RLP transfer of hepatitis C virus (HCV) subgenomic replicon. MS2-
modified HCV SGRJFH1 replicons: MS2-tagged bicistronic HCV RNA was generated by insertion of 6×, 12×, or 24 × 19-nt MS2 stem-loop at a PmeI 
restriction sites of the SGRJFH1. (b) Replication activity of modified replicons. Constructs were transcribed in vitro and transfected into Huh7.5 naive 
cells. Histograms show RT-qPCR analysis of G418-treated resistant clones probed for HCV RNA replication efficiency. Control SGRJFH1, SGRJFH1-MS2-6X, 
SGRJFH1-MS2-12X, SGRJFH1-MS2-24X; light to dark blue bars respectively. (c) Integrity of MS2 stem-loop in replicons. Following selection, MS2 insertion 
integrity was confirmed by RT-PCR with primers amplifying a region comprising the different repeats. A cellular actin RT-PCR was used as a control 
of RNA integrity following extraction (lower panel). Neo-IRES: sequence containing the forward and reverse primers. (d) Mobilization of MS2-tagged 
HCV replicons by MS2RLP in transfected Huh7.5 cells. Huh7.5 expressing the modified replicons was transfected with an Amphotropic expression 
plasmid (Ampho, sample 2); the WT p8.74 packaging construct and the Amphotropic plasmids (WT+Ampho, sample 3); the ΔZF packaging and the 
Amphotropic plasmids (ΔZF+Ampho, sample 4) and the ΔZF_MS2coat and the Amphotropic plasmids (ΔZF_MS2coat+Ampho, sample 5). Filtered 
supernatants were used to transfect naïve Huh7.5 cells. After G418 treatment, resistant clones were fixed, crystal violet-stained and counted to quantify 
replicon mobilization. Mean ± SD (n = 4) analyzed by Kruskal-Wallis analysis (***P < 0.01).
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precluded their DNA conversion following transfer. We thus looked 
for a possible DNA integration of the Cre recombinase gene in trans-
duced cells. As expected, no signal was detected for MS2RLPs and 
only ILV-Cre led to integrated copies (Figure 2e, sample 3 compared 
to 4). Taken together, our results validated the ability of the MS2RLP 
packaging system to promote efficient and specific mobilization of 
biologically active MS2-12X mRNA in all tested cell types.
MS2RLPs deliver subgenomic viral RNAs
We next investigated the mobilization of other types of cytoplas-
mic RNA with MS2RLPs. Hepatitis C virus (HCV) replicon RNAs, that 
autonomously replicate by expressing nonstructural viral genes 
products were used as a model for uncapped RNA.31 To enable 
specific mobilization of HCV-replicon RNA, MS2 stem-loop repeats 
were inserted at the 3’ end of the neomycin selection marker coding 
Figure 4 In vivo RNA delivery by MS2RLPs. (a) Bioluminescence in vivo analysis showing kinetics of luciferase expression in mice after injection of purified 
suspension of MS2RLP-Luc particles. A first group of animals received a suspension of the purified integrative lentiviral vector rLV-EF1-Luc (n = 2), and a 
second group received a suspension of purified MS2RLP-Luc (n = 4). A noninjected animal was a negative control. Measurements were carried out at 5 
hours up to 168 hours after systemic injection. (b) Quantitative measurement of luciferase. The top panel shows all the measurements from 5 to 168 hours, 
the bottom panel is an enlargement of the 5- to 24-hour period highlighting the differences between the two vectors exacerbated at 5 hours. Data are 
expressed in relative luminescence units. (c) In vivo analysis for YFP expression in ROSA 26 YFP mice after injection of purified suspensions of MS2RLP-Cre 
or rLV-EF1-Cre. YFP immuno-staining (green) on 20 µm thick cryosections of injected muscles of the left thigh. Nuclei were stained with Hoechst 33342 
(blue). Mice were injected with either rLV-EF1a-Cre (A–D) or MS2RLP-Cre (E–G); internal negative control is shown (H). Phosphate-buffered saline–injected 
muscle were not stained (data not shown). Photographs are representative of stained sections obtained from each individual animal (see text). Enlarged 
areas (white rectangles) B, C, and D are from a (rLV-EF1a-Cre); and F, G, and H are from E (MS2RLP-Cre). Scale bars: A and E = 1 mm, B–D and F–H = 100 µm.
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sequence upstream the of EMCV IRES governing HCV nonstructural 
gene expression (Figure 3a).31 Resulting constructs SGRJFH1-MS2-6X, 
SGRJFH1-MS2-12X, and SGRJFH1-MS2-24X harboring 6, 12, and 24 
copies of the MS2 motif respectively, were transcribed in vitro and 
transfected into Huh7.5 naive cells. Following G418 selection, we 
obtained resistant clones, except for the GND replication-defective 
HCV replicon (Supplementary Figure S3a). 5’UTR-specific RT-qPCR 
confirmed that G418-resistant Huh7.5 clones harbored HCV RNA 
and showed comparable replication efficiency (Figure 3b, samples 
2–5). To check for MS2-loop loss during HCV replication, RT-PCR 
primers amplifying the MS2 insertion site were designed and con-
firmed the stability of the insert (Figure 3c). Replicon functionality 
was finally assessed by detection of NS3 and NS5A nonstructural 
proteins (Supplementary Figure S3b). Having confirmed that MS2-
loop insertion was conserved during HCV replication, we next mobi-
lized the modified replicon by using MS2RLPs. Replicon-harboring 
Huh7.5 cells were transfected with p8.74 ΔZF_MS2coat or controls 
and resulting particles were used to transduce naive Huh7.5 cells. 
No resistant clones were obtained from controls (Figure 3d, samples 
2–4) or from wild-type SGRJFH1-replicating cells (Figure 3d, light blue 
bars compared to others in sample 5; Supplementary Figure  S3). 
Conversely, neomycin-resistant clones were obtained from MS2RLPs 
produced in cells hosting an MS2-tagged HCV-replicon (Figure 3d, 
sample 5, for the three shades of blue). Interestingly, the mobiliza-
tion efficiency appeared proportional to the number of inserted 
MS2 repeats (Figure 3d, sample 5). In transduced cells, specific HCV-
RNA RT-qPCR analysis confirmed the efficient replication of HCV 
RNA (data not shown). As the size of the SGRJFH1-MS2-24X is approxi-
mately 10,000 nt, its recruitment within MS2RLPs suggested that 
the system could deliver long RNAs. Thus, MS2RLPs were efficient in 
mobilizing uncapped RNA with an exclusive cytoplasmic replication 
cycle, such as the HCV genome. Moreover, it indicated that MS2RLPs 
could be produced in Huh7.5.
Efficient in vivo RNA delivery by MS2RLPs
We next determined whether MS2RLPs enabled systemic and local-
ized in vivo expression in mice. The ability to deliver RNA in vivo 
would be valuable for several applications in research and the clinic. 
To ensure the use of purified particles at high titers, an important 
condition to obtain relevant results in in vivo applications, we used 
VSV-G pseudotypes (see methods). Among the possible routes for in 
vivo delivery, two representative modes of injection were evaluated.
First, we checked caudal vein delivery using a purified prepara-
tion of MS2RLP (see methods). MS2RLP-Luc (1.7 × 1011 PP/ml) was 
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employed to determine the kinetics of luciferase expression with 
systemic injection in mice. A suspension of purified integrative 
rLV-EF1-Luc vector (2.1 × 108 TU/ml) was used as a positive control. 
Administration by the intravenous route induced a broad diffusion 
of the bioluminescent signal, which was quantified in the whole 
mouse body (except the tail signal). At 5 hours after intravenous 
injection of purified particles, we detected significant luciferase 
expression (818 relative luminescence units); the signal was still 
detectable 8 hours postinjection (234 relative luminescence units) 
and then disappeared at later times (Figure 4a,b, bottom panels, 
group MS2RLP-Luc). As expected for caudal vein injection, the bio-
luminescence signal was predominantly detected in the liver and 
spleen (Figure 4a). For comparison, the 5-hour time point measured 
in animals receiving the purified suspension of integrative rLV-EF1-
Luc vector gave a barely detectable signal in the liver and spleen 
(Figure 4a). For rLV-EF1-Luc, the signal was significant at 72 hours 
and almost 7 days (168 hours) were needed to reach the maximum 
level observed with MS2RLP-Luc (Figure 4b). These kinetics parallel 
those obtained in vitro and further emphasized the explosive and 
brief expression obtained with MS2RLP mRNA delivery as com-
pared to stable lentiviral expression.
To confirm the value of single-shot mRNA delivery, we examined 
the process with MS2RLP-Cre in ROSA26-YFP reporter mice.32 We 
locally injected MS2RLP-Cre (107 PP in 5 µl) into the biceps femo-
ris muscle of ROSA26-YFP reporter mice. Injected samples were 
collected from biceps femoris of five mice 7 days postinjection. As 
shown in Figure 4c, this model highlighted the efficiency of the 
nonintegrative MS2RLP-Cre system, which conferred expression of 
the YFP in a wide zone of injected muscle (Figure 4c, A, B, and C, 
as compared to nonaffected muscle zone H). MS2RLP-Cre spread in 
approximately 1 cm of the muscle, and this was comparable to the 
area reached with a purified integrative rLV-EF1-Cre vector used as a 
positive control (Figure 4c, E, F, and G). Altogether, in vivo data con-
firmed the potency of MS2RLPs to deliver functional mRNA locally 
or by systemically.
MS2RLPs containing transcription factor mRNA promote a cell-fate 
shift in human MSCs
Cell therapy applications could benefit from the transient expres-
sion of differentiation factors. Thus, we assessed the ability of 
MS2RLPs to trigger a shift in cell fate by expressing two transcription 
factors involved in osteoblastic differentiation. RUNX2 and DLX5 are 
master transcription factors inducing skeletogenesis in mesenchy-
mal stem cells.33 DLX5 is a member of the distal-less HD protein fam-
ily and has been implicated in the commitment of mesenchymal 
progenitors to the osteoblast lineage by the upregulation of RUNX2 
and OSTERIX. For RUNX2, we cloned the cDNA variant 1, type II iso-
form that is predominantly expressed in osteoblasts and is consid-
ered essential for osteoblastic differentiation.
Figure 5 MS2RLP delivery of transcription factors promote a cell-fate shift in human MSC-I. (a) MS2RLP effect on osteoblastic differentiation of human 
MSC-I. Results for RT-qPCR analysis of the expression of gene osteoblastic in immature human mesenchymal stem cells (MSC-l) after MS2RLP-RUNX2 or 
MS2RLP-DLX5 mRNA transfer. MSC-l cells precultured in EGM2 medium were transduced with 50,000 PP/cell of MS2RLP-RUNX2 (dark blue bars), MS2RLP-
DLX5 (light blue bars) or control cells with BMP4 (white bars). Following transduction, cells were maintained in αMEM supplemented with 2% FCS and 
mRNA expression of RUNX2, DLX5, iBSP, and OSTERIX was measured at 58 hours post-transduction. Significance was measured by one-sample t-test with 
the reference value fixed to 1, which corresponded to MSCs transduced with nonintegrative IDLV-Luc. Data are mean ± SD (n = 4) (*P < 0.05). (b and c) 
Gene Set Enrichment Analysis. Osteoblastic upregulated markers genes obtained after MS2RLP-DLX5 mRNA transfer into MSC-l cells. Osteoblastic markers 
were enriched (P = 0.012) (b). Osteoblastic upregulated markers genes obtained after MS2RLP-RUNX2 mRNA transfer into MSC-l cells. Osteoblastic markers 
were enriched (P = 0.0026) (c). (d and e) Representative heat maps highlighting osteoblastic genes with increased and reduced expression. The heat 
map shows the effect of MS2RLP-DLX5 mRNA transfer in MSC-l with a reference of MSC-l transduced with lentiviral particles IDLV-Luc (d). The heat map 
shows the effect of MS2RLP-RUNX2 mRNA transfer in MSC-l with a reference of MSC-l transduced with lentiviral particles IDLV-Luc (e). Red: genes with 
increased expression; and green: gene with decreased expression. Colour intensity represents the range of difference. MEM, Minimum Essential medium.
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In a first study, human osteosarcoma MG63 cells, exhibiting an 
immature phenotype reminiscent of MSCs,34 were used to assess the 
biological effect of DLX5 or RUNX2 mRNA transfer. MG63 were trans-
duced with MS2RLP-RUNX2 or MS2RLP-DLX5 (50 × 103 or 100 × 103 
MS2RLPs PP/cell) and cultured with or without the osteogenic dif-
ferentiation factor BMP4.35 Retroviral vectors stably expressing the 
transcription factors were used as positive controls. In the presence 
of BMP4, and 10 hours after transduction, DLX5 and RUNX2 mRNA 
transfer induced the endogenous forms of RUNX2 and DLX5 respec-
tively (Supplementary Figure S4a,b; dark blue). In cells transduced 
with MS2RLP-RUNX2 or MS2RLP-DLX5 and without BMP4, the PTHR1 
gene showed increased mRNA expression (Supplementary Figure 
S4c, dark blue), confirming that MS2RLP RNA delivery could induce 
transcription of osteoblastic genes.
Next, we examined lineage commitment in highly immature pri-
mary human MSC-like cells (MSC-l)36 not expressing RUNX2.37 MSC-l 
cells were transduced twice at 30 hours intervals, with MS2RLP-
RUNX2 or MS2RLP-DLX5 (50 × 103 MS2RLP PP/cell, see methods). 
Controls were MSC-l transduced with IDLV-Luc or left untransduced 
and BMP4-treated, a condition known to consistently differentiate 
MSCs into functional osteoblasts.38 At 58 hours post-transduction, 
endogenous genomic RUNX2 or DLX5 mRNA level significantly 
increased (Figure 5a). In addition, the osteoblastic marker integ-
rin-bone sialo-protein (iBSP) was upregulated in both conditions 
(Figure 5a). Conversely, the osteoprogenitor master factor OSTERIX 
showed no change in expression (Figure 5a), suggesting a commit-
ment of MSC-l toward an early osteoblastic lineage stage.
To complete the study, we analyzed the MSC-l transcriptome 
following transduction and with IDLV-Luc as a reference. Principal 
component analysis showed that MS2RLPs expressing RUNX2- or 
DLX5-mRNA promoted the preferential expression of osteoblastic 
genes in MSC-l (Figure 5b,c). However, genes from MS2RLP-DLX5-
modified cells were better clustered in the same branch than those 
from MS2RLP-RUNX2-modified cells (Figure 5d,e and Supplementary 
Figure S5), suggesting that MS2RLP-DLX5 may be more potent in 
inducing changes in gene expression. Detailed analysis of significant 
gene expression changes confirmed the increase in RUNX2, DLX5, 
and iBSP levels (Supplementary Tables S2 and S3). We identified 
several osteoblastic markers among other upregulated genes, such 
as PTGS2 and FOSB in MS2RLP-RUNX2 cells and BMP8, VDR, ENPP1, 
MEIS2 in MS2RLP-DLX5 cells (Figure 5d,e and Supplementary Tables 
S2 and S3). Interestingly, we confirmed previous observation show-
ing that DLX5 induced RUNX2 whereas RUNX2 failed to induce DLX5 
(Supplementary Table S2; Supplementary Figure S5a).39 In addition, 
among upregulated genes by MS2RLP-RUNX2, we identified STMN2, 
a gene induced in adipose and bone marrow-derived stromal cells 
under pro-osteoblastic differentiation conditions.40 We confirmed 
the consistent and early upregulation of STMN2 mRNA expression 
after BMP4 addition on highly immature mesenchymal stromal-like 
cells (Supplementary Figure S5b,c). Finally, we identified a series of 
common genes with significant expression changes upon MS2RLP-
RUNX2 or -DLX5 transfer and BMP4 addition, conditions known 
to consistently differentiate MSC-I into functional osteoblasts38 
(Supplementary Figure S6a). Regarding shared upregulated genes 
in BMP4-induced cells and under the MS2RLP-RUNX2 or -DLX5 
condition, the bone/skeletal development process was clearly 
highlighted by Gene Ontology terms (Supplementary Figure S6b), 
especially for MS2RLP-DLX5 and BMP4 conditions (Supplementary 
Figure S6b). Overall, MS2RLP-RUNX2 or MS2RLP-DLX5 consistently 
committed human primary MSC-I toward an early osteoblastic 
lineage, confirming that MS2RLPs could contribute to promoting 
cellular reprogramming (Supplementary Tables S4 and S5).
DISCUSSION
In the present report, we described a versatile and efficient cell-
transfer system for mRNA or other types of RNAs. Our results showed 
that exploiting MS2-Coat and its cognate 19-nt stem-loop, led to sig-
nificant RNA transfer via modified lentiviral particles in all types of 
cells in vitro or in vivo (Figures 2–5). As compared to other retroviral 
platforms, transfer efficiency was high, without any requirement for 
a selection process10,41 (Figures 2–4). In a therapeutic perspective, 
an advantage of the MS2RLP system is its ability to utilize lentiviral 
platforms already validated in clinical settings. Moreover, the RNAs 
transferred by the MS2RLPs are directly expressed into the cyto-
plasm, which reduces the risk of integration, an important safety 
consideration for human use (Figure 2e). This characteristic is in con-
trast to transient episomal DNA vectors, such as IDLV, which lead 
to some integration at low frequency.42 Although our studies have 
been performed with lentiviral vectors other retroviruses could be 
similarly modified. Introducing MS2-Coat sequence within the p12 
protein from a gammaretrovirus-derived vector6 also permitted 
transfer of RNAs harboring the 19-nt stem-loop (Supplementary 
Figure S7). In addition, like for other vectors, it could be possible to 
adapt MS2RLPs to a cell type by selecting the envelope exposed at 
their surface.
The high efficiency of RNA transfer by the MS2RLPs is most likely 
related to an increased ratio of RNA to particle content, resulting 
in directly detectable and significant biological activity (Figure 2). 
This is extremely valuable when seeking editing or reprogramming 
functions, especially if a combination of gene products is required.43 
Additionally, RNAs from MS2RLPs are rapidly bioavailable (Figures 
2b and 4b), leading to high and short-term expression of the trans-
ferred messenger. This characteristic is of great value for genome 
engineering. In lentiviral transgenesis, the early expression of the 
transgene following egg-injection is expected to reduce the risk of 
genome chimerism in the progeny.44 Short-term and efficient RNA 
expression would also be valuable in several other applications, 
such as vaccination and immunotherapy.45 However, as highlighted 
by the comparison of the kinetics of expression of luciferase and 
GFP (Figure 2a,b compared to c and S2), the half-life of the trans-
ferred protein could be a concern as was shown recently with fluo-
rescent proteins.30 Therefore, the biochemistry of the transferred 
protein is expected to affect the requirements for designing a useful 
vector. Several methods could be used to modulate the level of pro-
tein expression, including the stabilization of the RNA, with modi-
fication of nucleotide usage,45 or by using defined 5′ and 3′ UTRs.11 
For a more sustained expression, viral subgenomic replicons would 
offer a relevant alternative. Accordingly, we showed MS2RLP-based 
transfer of an HCV replicon in Huh7.5 cells (Figure 3). To build new 
transfer-platforms, several alternative RNA-replicons exist. Recently, 
replicons derived from Venezuelan equine encephalitis virus (VEE) 
and expressing reprogramming genes were shown to support iPS 
formation.43 To ensure safety after obtaining the intended biological 
effect, eradication of the reprogramming replicon is expected and 
could be triggered by use of cell-fate specific miRNA.46 Nevertheless, 
a case-by-case analysis could be useful to evaluate the innate 
immune response of the target cells, since it could block replication 
of the replicon.47 For example, we were unsuccessful in expressing 
reporter genes from an HCV-replicon transferred by MS2RLP in pri-
mary human MSC (data not shown).
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MS2RLPs are versatile vectors as demonstrated here by in vitro 
transfer of mRNAs in cell lines, human iPS, primary human mesen-
chymal cells and mouse liver or muscles in vivo. While we did not 
compare MS2RLP to all RNA-transfer methods, our results showed 
that human primary CD34+ cells, a clinically relevant target not 
easily transfected using electroporation or chemical transfection, 
could express high level of a transgene following MS2RLP trans-
duction (Figure 2c and Supplementary Figure S2b). As for other 
cell types, CD34+ cells expressed the transgene at a level similar to 
that reached by IDLV (Figure 2c1–c2). Yet, the kinetic was slightly 
different, MS2RLP giving a higher and faster transgene expression 
at early time points. Notably, the expression induced by MS2RLP in 
CD34+ cells was not conditioned by the addition of cytokines.29
The diversity of RNAs that could be transferred by MS2RLPs is 
only dictated by the presence of the 19nt MS2 stem-loop. Hence, 
the molecular structure of transferred RNA is adaptable and ame-
nable to regulation with some tools already available.7 Here, we 
have shown that mRNA and RNA-replicon were mobilized (Figures 
1–4), a property which could no doubt be extended to LncRNA or 
circRNA as modulators or regulators of gene expression.48,49 The 
transfer of interfering RNAs will need more investigations because 
the pathway of miRNA maturation involves both nuclear and cyto-
plasmic steps as well as cleavages, which can separate the recruit-
ing sequence from the active part of the molecule. An aspect we 
have indirectly explored is the size capacity and limits of the trans-
ferred RNA. Our experiments showed that the short GFP sequence 
and HCV replicon, of approximately 10 kb (Figures 2 and 3), could 
be transferred efficiently. This covers most of the needs in the field 
of RNA transfer. Similarly, by recruiting the RNA independently of 
dimerization (Figure 1) and with more than four molecules per 
particle (Supplementary Figure S1b), MS2RLPs should permit the 
cotransfer of different species of RNA. For the reprogramming 
experiments, several different osteogenic factors could be used, 
and the opportunity to sequentially deliver these factors through 
MS2RLPs might be very valuable. Among potential applications 
are gene-editing methods.3 The opportunity to get highly efficient 
Cre recombinase activity after mRNA MS2RLP delivery (Figures 
2d and 4c) paves the route to transfer of other systems such as 
those based on CRISPR/Cas (a preliminary experiments is given in 
Supplementary Figure S2f).3 For the transfer of the CRISPR/Cas9, the 
multiplexing of several species of RNAs, one coding Cas9 and others 
the sgRNA, would be needed. Moreover, it will be a complex chal-
lenge to obtain optimal stoichiometry following encapsidation of 
the different RNA species into the same particles.
Considering in vivo applications, our results further illustrate the 
efficacy of MS2RLPs for the delivery of genetic information. For vac-
cination, besides the expression of immunogenic proteins by RNAs, 
immune response could be improved by transferring subgenomic 
replicons. Expressing viral nonstructural genes could contribute to 
the clearance of cells infected by the native virus. By mobilizing an 
HCV replicon from Huh7.5 cells (Figure 3), we showed that MS2RLPs 
were also compliant in terms of production and could be eligible for 
in vivo local production of vaccinating particles.50 In the mouse mus-
cle in vivo, Cre expressing MS2RLPs allowed for a spread of the exci-
sion over 1 cm (Figure 4c). Such diffusion is broad and equivalent to 
that obtained with direct injection of nonenveloped vectors such as 
adeno-associated virus-based vectors.51,52 Systemic injection, while 
it mainly directs the vector load in the liver and spleen (Figure 4), 
offers a relevant alternative to delivering active RNAs. As mentioned 
above, organ specificity could be addressed by choosing the most 
adapted cell-penetrating envelope.
We also applied the system in a cell therapy approach, primary 
MSC-l (Figure 5 and Supplementary Files). Our data confirmed that 
transfer of bone specific transcription factor via MS2RLPs promoted 
osteogenesis induction (Figure 5). However, the protocol evaluated 
here proved to be limited to the priming of the MSC-l. We neverthe-
less identified OSTERIX, STMN2 and other genes as possible targets 
to trigger a more profound fate-shift toward the osteoblast pheno-
type. There is currently no definitive recipe to achieve this process 
in culture.53 Adapting MS2RLPs to high-throughput screening pro-
cedures will help to identify key factors and protocols for controlled 
administration of selected genes.
In conclusion, thanks to high titers on primary cells as well as in 
vivo, the new MS2RLPs described here, offer a significant and impor-
tant alternative in the field of RNA delivery. Because of their versa-
tile nature in packaging various types of RNAs, MS2RLPs have broad 
potential for application, including stem cell-differentiation, immu-
notherapy and genome editing.
MATeRIAlS AND MeTHODS
Packaging vector and plasmid expression constructs
HIV-I-derived MS2RLP. An MS2 containing HIV-I-derived vector was gener-
ated by substituting the NC’s second zinc finger (ZF2) domain with the MS2 
coat protein. The ZF2 domain was removed from p8.74 lentiviral plasmid 
using assembly PCR. The upstream region of the deletion site was amplified 
by using P8.74bZF-for: CCgCggCCgCgTTgACgCgCA (containing a Not-I site) 
and P8.74bZF-rev: CAgTgTTAACgCCCTTTTTCCTAgg (containing a HpaI re-
striction site). The downstream region of the deletion site was amplified us-
ing P8.74aZF-for: ATgCggCCgCgTTAACACTgAgAgACAgg (with a Not-I site) 
and P8.74aZF-rev: ggCTgATATCTAATCCCTggTgTCTC (containing a EcoRV 
site). After subcloning into PGEMT-easy plasmid, vectors were NotI/EcorV 
digested and reassembled into NotI/EcoRV digested p8.74 plasmid to gen-
erate p8.74∆ZF vector (ΔZF). The MS2 Coat protein coding sequence was 
amplified from LMNI-MS2-NLS-GFP plasmid, kind gift of P.D Bieniasz (Aar-
on Diamond AIDS Res. Center, New York), using HpaI containing primers 
MS2Coat-HpaI-for: TTgTTAACATggCTTCTAACTTT, and MS2Coat-HpaI-rev: 
CCgTTAACgTAgATgCCggAgTT and was inserted into p8.74∆ZF digested by 
HpaI leading to an in-frame cloning and generating p8.74 ∆ZF_MS2Coat 
(ΔZF_MS2coat) Coat vector (Figure 1).
Engineering mRNA. To enable the mobilization of mRNA into lentiviral par-
ticles, 12 repeats of the MS2 stem-loops were inserted into the expression 
vector pcDNA3.1 (Life Technologies SAS, Saint Aubin, France) containing the 
luciferase gene reporter. PCR and specific primers were used to obtain the 
entire luciferase Firefly sequence by PCR (Table 1), which was cloned into 
pcDNA3.1(-) vector (Life Technologies SAS) at the HindIII and KpnI sites to 
generate pcDNA-luciferase (pLuc). To generate pcDNA-luciferase-MS2-12X 
(Luc_MS2_12X), fragment containing 12 repeats of MS2 was obtained by 
digestion of pGemTeasy-MS2-12X plasmid with BamHI. The obtained frag-
ment was blunted with DNA polymerase I large (Klenow) fragment (5,000 
units/ml; New England Biolabs, Evry, France) and inserted into 3’ of luciferase 
gene in pcDNA-Luc plasmids previously digested with KpnI and treated 
with DNA polymerase I large (Klenow) fragment (Figure 1).
In parallel, a pcDNA-EF1-Cre-MS2_12X plasmid was generated. To 
construct this vector, a pCMV-luciferase sequence was deleted from the 
pcDNA-luciferase-Vimentin-MS2_12X vector and substituted by a pEF1-
Cre sequence amplified from a previous construct. The plasmid was gener-
ated by using the In-Fusion HD cloning kit (Clontech Laboratories). To avoid 
recombination, MS2 stem-loops-containing plasmids were grown at 32 °C.
For integrative and integrative-deficient lentiviral vectors, we used three 
different self-inactivating expression vectors, pLV-EF1-GFP, pLV-EF1-Luc, and 
pLV-EF1-CRE, based on the backbone described by Dull et al.26 These vectors 
encode the GFP, the luciferase or the CRE recombinase, respectively under 
control of the human elongation factor 12α promoter (EF1a).
MS2 tagging of HCV RNA. MS2 stem-loops from pSL-MS2-24 plasmid (gift 
from R.H. Singer, Albert Einstein College of Medecine, Bronx, New York un-
der MTA) were introduced into the JFH-1 HCV subgenomic replicon cod-
ing sequence. A fragment containing 24 repeats of the MS2 recognition 
RNA motif was obtained by EcorRV/BamHI digestion and sub-cloned into 
pGEMT-easy vector. Smaller fragments containing 6 and 12 repeats of MS2 
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motif were amplified by using MS2-BamHI-for: ACCCgggCCCTATATATg-
gATCC forward primer and the reverse primers MS2-BamHI-6X-rev: ATg-
gATCCgTgATTCCCCg or MS2-BamHI-12X-rev: TAggCAATTAggATCCTTAggAT 
containing BamHI restriction site. Resulting PCR products were sub-cloned 
into pGEMT-easy vector. MS2 repeats harbouring pGEMT constructs were 
then BamHI-digested, Klenow treated, and inserted into pSGR-JFH1-Neo 
subgenomic replicon coding plasmid at the PmeI restriction site (Figure 3). 
As above, MS2 stem-loops-containing plasmids were grown at 32 °C.
Viral vector production and quantitation
Amphotropic pseudotyped lentiviral particles. Productions were performed in 
293T cells (ATCC CRL-11268) seeded at 4.2 × 106 cells per plate into a 10-cm 
dish and grown overnight in Dulbecco’s modified Eagle medium (DMEM) 
Glutamax (Life Technologies, Carlsbad, CA) supplemented with 10% heat-
inactivated fetal calf serum, 100 µg/ml Stretomycin, 100 U/ml Penicillin and 
placed at 37 °C in a humidified atmosphere of 5% CO2 in air. Fugene 6 trans-
fection reagent was used to transfect cells with 1 µg p8.74ΔZF-MS2-coat, 1 
µg of pCMV-Env encoding 4070A amphotropic envelope, 80 ng pEGFPC1 
for normalization and 2.52 × 10−13 mole of Luc_MS2_12X. After 8 hours, the 
medium was removed and cells were washed with phosphate-buffered sa-
line (PBS), then fresh medium was added. After 48 hours, particles-contain-
ing supernatants were harvested and filtered through a 0.45-µm pore filter 
(Millipore, Saint Quentin en Yvelines, France).
VSV-G-pseudotyped lentiviral particles. Productions were performed in a 
10-layer CellSTACK (6,360 cm2, Corning) using 293T cells. The tri-transfection 
mix was composed of three plasmids: pENV carrying the VSVG envelope, 
p8.74 (WT) or p8.74 ΔZF_MS2coat or p8.74 mutated in the D64L to produce 
(IDLV), and pLV-EF1-cDNA/pMS2-cDNA. Twenty-four hours post-transfection 
by standard calcium phosphate procedure, the supernatant was discarded 
and replaced by fresh nonsupplemented DMEM. Cells were incubated at 37 
°C in a humidified atmosphere of 5% CO2 in air. After medium change, the 
supernatant was collected. Fresh nonsupplemented DMEM was added and 
the cells were incubated prior to further harvest. Each harvest was clarified 
by centrifugation for 5 minutes at 3,000g before being microfiltered through 
a 0.45-µm pore-size sterile filter unit (Stericup, Millipore). The whole set of 
harvest were then pooled to supply the crude harvest.
Viral vectors concentration and purification. The crude harvest was first con-
centrated by tangential flow ultrafiltration with polysulfone hollow-fiber 
cartridges. The supernatant was then diafiltered against DMEM buffer, and 
retentate was recovered and further concentrated on ultrafiltration dispos-
able units.
Functional particle quantification by qPCR. Transduction unit titration assays 
were performed as follows. HCT116 cells were seeded in 96-well plate in 
100 µl of DMEM supplemented with 10% heat-inactivated foetal calf serum, 
100 µg/ml Stretomycin, 100 U/ml Penicillin. Twenty-four hours later, five se-
rial dilutions were performed with each vector sample and an rLV-EF1-GFP 
internal standard. The cells were transduced in presence of 8 µg/ml Poly-
brene (Sigma). For each sample series, one well of nontransduced cells is 
added as control. Three days post-transduction, cells were trypsinized and 
the titer (transducing units/ml) was determined by qPCR after extraction 
of genomic DNA using the Nucleospin tissue gDNA extraction kit (Mach-
erey-Nagel, Hoerdt, France). The titer determined in transducing units per 
ml (TU/ml) using qPCR was normalized by an internal standard whose titer 
was previously determined by FACS.
Physical particle quantitation by p24 ELISA. The p24 core antigen is detected 
directly on the viral supernatant with use of a HIV-1 p24 ELISA kit (Perkin 
Elmer, Courtaboeuf, France). The reaction is based on an antigen capture 
recognized with a biotinylated polyclonal antibody against HIV-1 CAp24. 
The resulting complex is revealed by a streptavidin–horseradish peroxidase 
conjugate after incubation with ortho-phenylenediamine-HCl, producing a 
yellow colour proportional to the amount of CAp24 captured. The absorb-
ance of each well is measured; quantification is obtained as compared to a 
standard curve established with reference HIV-1 CAp24 antigen samples, 
on a microplate reader. The viral titer expressed in physical particles per ml 
is calculated from the amount of p24 knowing that 1pg of p24 corresponds 
to approximately 104 physical particles.
Quantitative real-time RT-qPCR. To assess mRNA mobilization into lentiviral 
particles, RNA was extracted from 140 µl lentiviral particles containing su-
pernatants by use of the QIAamp viral RNA Mini-kit (Qiagen, Courtaboeuf, 
France). In total, 4 µl RNA treated with TURBO DNAse (2 U/µl) was used for 
cDNA synthesis with the Superscript First-strand Synthesis System (Life Tech-
nologies). Luciferase RNA copies were quantified by RT-qPCR, with a Light 
Cycler480-II system (Roche, Boulogne-Billancourt, France). RT-qPCR ampli-
fication: 2 µl of reverse transcriptase product, 1× SYBR Green I master mix 
(Roche), 10 µmol/l of each primer and RNase-free water to a final volume 
of 20 µl was quantitated by 5-minute preamplification at 95 °C, 45 cycles: 
10” at 60 °C and 10” at 72 °C, followed by melting curve and cooling steps. 
PCR amplification was obtained with primers allowing specific amplification 
of the luciferase, forward, 5′-CAACTgCATAAggCTATgAAgAgA-3′ and reverse, 
5′-ATTTGTATTCAgCCCATATCgTTT-3′. The RNA copy number was calculated 
by an external standard curve of serial dilution of a pBullet-Luc plasmid.
Quantitative real-time RT-qPCR on serial dilution. Since the CAp24 normali-
zation could be someway misleading, we designed an unbiased experi-
ment to estimate MS2RLP RNA-content. Supernatant from cells producing 
the MS2RLP or a standard lentiviral vector (ILV) were serially diluted, six 
serial one-half dilutions from crude supernatant, and the amount of RNA 
per sample was measured by RT-qPCR (see above for RT-qPCR). From the 
data, we draw a curve and derived their respective equation (Supplemen-
tary Figure S1b). The curves are theoretically expected to converge to the 
intercept and their respective slopes are proportional to the amount of RNA 
per particle. The ratio calculated using MS2RLP slope over ILV slope gives 
the factor of difference in RNA content between the two types of particles, 
independently of the structure of the particles. The experiments were re-
peated independently three times in triplicate.
Electron microscopy
Transmission electron microscopy was performed at IMPMC (UMR 7590, 
CNRS-UPMC-IRD-MNHN, Paris, France). For negative staining, samples pro-
duced at about 1012 PP/ml were diluted 50-fold and 5 μl were dropped onto 
plain carbon grids, blotted, and immediately stained for 1 minute with 5 μl 
of 2% uranyl acetate before blotting again. The sample was allowed to dry 
before observation under a LaB6 JEOL JEM2100 electron microscope (×52,800 
magnification). Data were digitally recorded by use of a 2k × 2k Gatan camera.
Luciferase assay and luciferase kinetics
On the day before transduction, 60,000 293T cells were seeded in 96-well 
plate. The day of transduction, test samples of MS2RLP were applied to cells 
with or without 3 µg/ml puromycin. This translation inhibitor was added 1 
hour before transduction. For 4070A envelopes transduction was realized in 
presence of Polybrene (5 µg/ml, Sigma-Aldrich, Saint Quentin Fallavier, France) 
and under centrifugation for 1 hour at 1,900 rpm and 37 °C. Following trans-
duction, luciferase expression was determined by use of the Bright-Glo lucif-
erase assay (Promega, Charbonnières-les-Bains, France) and a Centro LB 960 
luminometer (Berthold Technologies). The assay was performed in triplicate.
For the kinetics, HCT116 cells were seeded in six-well plate and incubated 
24 hours at 37 °C in 5% CO2. Transduction by ILV, IDLV, or MS2RLP was carried 
out in presence of 4 µg/ml Polybrene with 2 × 105 physical particles/cell. The 
transduction-supernatant is removed 5 hours later. From 4–24 hours post-
transduction, cells were harvested and luciferase expression was analyzed 
using the One-Glo Luciferase assay (Promega) as above. The assay was per-
formed in triplicate.
Cre recombinase in vitro
HCT116 cells were transduced by an ILV-EF1-Lox-dsRed-Lox lentiviral vec-
tor at a multiplicity of infection of 20 with 4 µg/ml Polybrene. Six days later, 
polyclonal cells were cloned by limit dilution by seeding 0.5 cells/well in 
96-well plate. Clone #14 was selected by FACS (MACS Quant VYB, Miltenyi, 
Paris, France). Polyclonal or clone #14 HCT116-Lox-dsRed-Lox cells were 
transduced with IDLV-CRE or MS2RLP-CRE with 2 × 105 PP/cell. 14 days post-
transduction, the dsRed expression was analyzed by FACS. The assay was 
performed in triplicate.
Hematopoietic cell transfection and transduction
Hematopoietic cord blood cells were obtained from the “Fondation Générale 
de Santé” and the “Assistance Publique-Hôpitaux de Paris”. CD34+ cells were 
purified using CD34 microbeads (Miltenyi Biotec) and the autoMACS Pro 
separator (Miltenyi Biotec). For transduction and transfection experiments, 
cells were grown in X-VIVO20 (Lonza, Levallois, France) complemented with 
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cytokines (Peprotech), including hSCF (100 ng/ml), hTPO (100 ng/ml), hFLT3L 
(100 ng/ml), and hIL3 (60 ng/ml).
The nonintegrative GFP vector (IDLV-GFP) supernatant was produced 
by transient transfection of HEK293T cells in 10-cm dishes, using Fugene 6 
(Promega). Plasmids were a self-inactivating (SIN) and Tat-independent lenti-
viral vector encoding GFP under the control of the EF1α promoter/enhancer 
(LTGCEGFP1), and three packaging plasmids including HPV275D64A (HIV1 
gag/pol with a D64A mutation in integrase), p633 (expressing rev), and ΨN15 
(VSVG).54 IDLV supernatants were collected 48 hours after transfection, fil-
tered through a 0.45-µm filter, concentrated ≈1,000-fold by ultracentrifuga-
tion and stored at −80 °C; ELISA CAp24 concentration was 13.4 ± 0.4 µg/ml.
The GFP RNA vector (MS2RLP-GFP) was produced by transient transfec-
tion of HEK293T cells in 10-cm dishes, using Fugene 6. Plasmids transfected 
consisted of the GFP encoding plasmid pVAX2-EGFP-MS2-12X, and three 
packaging plasmids including p8.74_ΔZFMS2Coat, p633 (rev) and ΨN15 
(VSVG). pVAX2-EGFP-MS2-12X was made by subcloning EGFP-MS2-12X 
from pBullet-EGFP-MS2-12X in pVAX2. It encodes EGFP under the control 
of the Human cytomegalovirus immediate-early (CMV) promoter and has 
a bovine growth hormone polyadenylation signal. pVAX2 was obtained by 
replacing the cytomegalovirus promoter of pVAX1 (Life Technologies) by 
that of pCMVβ (Takara), as described.55 VLP supernatants were collected 
48 hours after transfection, filtered through a 0.45-µm filter, concentrated 
≈1,000-fold by ultracentrifugation and stored at −80 °C; ELISA CAp24 con-
centration was 27.4 ± 3.2 µg/ml.
The GFP mRNA was obtained from Trilink Biotechnologies. It carries an 
antireverse cap analog at the 5’ end, it is polyadenylated, and is modified with 
5-methylcytidine and pseudouridine to decrease nuclease activity and Toll-like 
receptor activation, mimicking a fully processed mature mRNA. Transfection 
used the 4D-Nucleofector X Unit and the P3 Primary Cell 4D-Nucleofector X 
Kit (Lonza) or the TransIT-mRNA Transfection kit (Mirus Bio). A control plasmid 
expressing GFP (pmaxGFP) is included in the Nucleofector X kit.
GFP expression was determined by flow cytometry using the MACSQuant 
Analyser (Miltenyi Biotec) and the FlowJo software (Tree Star) for vector 
transduction or the FACSCanto II and the Diva software (Becton Dickinson) 
for plasmid and mRNA transfection.
GFP expression in Hela cells
50 × 103 Hela cells were seeded in six-well plates 24 hours before transduc-
tion. Approximately 1 × 108 physical particles per well were used. After 24 
hours, cells were washed with saline solution and analyzed by flow cytome-
try (FACS) or cultured for a total of additional 7 days to follow GFP expression.
Transduction of human induced pluripotent stem cells
The BBHX8 hiPSC line was maintained on Matrigel-coated culture wells (BD 
Biosciences, San Jose, CA) in mTeSR1 (Stemcell Technologies, Vancouver, BC, 
Canada) at 37 °C in 5% CO2 incubator with daily medium change and by using 
Gentle Cell Dissociation Reagent (Stemcell Technologies) for cell passaging. 
Three days before transduction, 200 × 103 cells were seeded in 12-well plate. 
Transduction was performed for 24 hours with different amount of viral 
particles, in ng of CAp24, and with cells at 60–70% confluence. Before FACS 
analysis, cells were detached using TrypLE (Life Technologies).
HCV RNA in vitro transcription
After XbaI linearization of plasmids, modified and control HCV replicons 
RNAs were synthetized in vitro by transcription using RiboMAX large-scale 
RNA production system T7 (Promega). After DNAse treatment, RNAs were 
purified with RNA clean-up kit (Macherey-Nagel) before transfection.
HCV RNA transfection and quantitative real-time PCR
In vitro synthetized HCV replicons, RNAs were transfected into Huh7.5 cells 
by electroporation: trypsinized cells were washed in PBS, and 2 × 106 cells 
were resuspended in 1 ml PBS and placed in 0.4-cm electroporation cuvettes 
(Biorad). Electroporation with a 950 μF and 260 V pulse in a Genepulser sys-
tem (Biorad). After electroporation, cell suspension was transferred in 10-cm 
plates containing medium and incubated at 37 °C under standard condi-
tions. Two days after transfection, cells were selected with 1 mg/ml geneticin.
Total RNAs from transfected Huh7.5 and Huh7.5 HCV were extracted 
(Nucleospin RNAII kit, Macherey–Nagel), and 0.5 µg of RNA was used for 
cDNAs synthesis (Super-Script First-Strand II Synthesis System, Invitrogen). 
JFH1 RNA quantification was performed by qPCR with JFH1 and β-actin-
specific primers (Supplementary Table S1) using SYBRGreen incorporation 
(SYBRGreen I MASTER). Cycling conditions were 5 minutes preamplification 
at 95 °C, 45 cycles (10” 95 °C, 10” 60 °C, 10” 72 °C) (Light-Cycler-480-II, Roche).
MS2RLP-HCV production and colony formation assay
For HCV replicon RNA mobilization, 2.5 × 106 Huh7.5 HCV cells harbor-
ing JFH1-derived subgenomic replicons were transfected using FuGENE-6 
(Promega) with 1.5 µg Gag-Pol coding plasmids, 1 µg of pCMV-Env Ampho 
plasmid. Supernatant from transfected cells were harvested and filtered 
(0.45-µm filters, Millipore) at 24, 36, 48, and 60 hours post-transfection. Naive 
Huh7.5 was transduced using 2 ml of filtered supernatants. Transduction was 
facilitated by 45 minutes spinoculation at 1,200 × g with 5 µg/ml polybrene 
(Sigma-Aldrich). Transduced cells were selected in 1 mg/ml geneticin 48 
hours after transduction. Resistant clones were fixed in 2% paraformalde-
hyde, crystal violet stained and counted, using ImageJ cell counter pluggin. 
Results were obtained from four independent experiments performed in 
duplicates. After transduction, some clones were expanded forfurther analy-
sis, by HCV RNA-specific RTqPCR or western blotting.
Bioluminescence kinetics in mice
Seven-week-old Balb/c male mice (Janvier Labs, Saint Berthevin, France) 
received 200 µl of various vector suspensions by injection in the tail vein 
with 29G syringes. Injections were performed under a PSM II, according to 
a protocol validated by the local ethic committee. Animals were housed in 
ventilated racks in IVC cages in accordance with current European regula-
tions. Two mice were given a suspension of purified Integrative lentiviral 
vector rLV-EF1-Luc, and a group of four animals received a suspension of 
purified particles MS2RLP-Luc and another group of four animals received a 
standard suspension of particles NILP-MS2-Luc. A noninjected animal served 
as negative control for background. Mice were anesthetized by continuous 
inhalation of 1.5% Isoflurane in O2-enriched air. Each measurement of lucif-
erase was carried out 15 minutes after intraperitoneal injection of 300 mg/
kg D-luciferin (Promega) with an Andor camera, image acquisition with the 
Solis software. The acquisition time was 5 minutes, and resulting images 
were processed and standardized with ImageJ software (U.S. National 
Institutes of Health, Bethesda, MD, http://imageJ.nih.gov/ij/ , 1997-2015).
In vivo YFP expression in ROSA 26 YFP reporter mice after injection 
of MS2RLP-Cre or rLV-EF1-Cre
Eleven ROSA 26 YFP reporter mice32 were injected with ILV EF1a CRE (n = 5), 
MS2RLP (ARN) CRE (n = 5), or PBS (n = 1). Mice were anesthetized by continu-
ous inhalation of 1.5% Isoflurane in O2-enriched air. A 5-mm incision of the 
skin above the left thigh was performed to visualize the biceps femoris. Five 
microliters of concentrated vectors or PBS were manually injected in a single 
injection site in the bicept femoris. The total dose injected corresponded to 
3 µg of CAp24 and 0.5 µg for MS2RLP (ARN) CRE and ILV EF1a CRE vectors 
respectively. At 7 days after injection, the complete left thigh of mice were 
removed and fixed overnight in 4% paraformaldehyde in 1× PBS. Fixed tis-
sues were cryoprotected in 15% sucrose in 1× PBS for 48 hours, frozen at 
−50 °C in isopentane and sliced in 20-µm-thick sections. The section axis 
was parallel to the global orientation of muscle fibers in the biceps femo-
ris. YFP expression was observed after immunostaining as described previ-
ously56 with rabbit anti-GFP primary antibody (1:1,000; Molecular probes) 
and Alexa-fluor 488 goat anti-rabbit IgG as secondary antibody (1:1,000; 
Invitrogen). Nuclei were stained with Hoechst 33342. Photographs of whole 
sections were acquired with a Hamamatsu NanoZoomer scanner (20× reso-
lution) and enlargement of selected areas were photographed with a Leica 
DM5000 epifluorescent microscope equipped with a Leica color camera.
mRNA transfer study in primary bone marrow cells mesenchymal 
stem cells
MSCs transduction with lentiviral particles. The study involved human bone 
marrow cells isolated from femoral heads from four healthy volunteers un-
dergoing orthopaedic surgery. The study followed the ethical guidelines of 
the University Hospital of Tours (Tours, France) and was approved by the eth-
ics committee Comité de protection des personnes (Tours - Région Centre 
(Ouest-1)). Cells were cultured in endothelial growth medium 2 (Promocell, 
Heidelberg, Germany) for 14 days. Three days before the transduction, cells 
were seeded in 12-well plates at 5,000 cells/cm2 and maintained in EGM2 me-
dium. Transduction involved 50 × 103 viral particles per cell (MS2RLP-RUNX2, 
MS2RLP-DLX5, or IDLV-Luc produced by Vectalys) with Polybrene (5 µg/ml), 
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and cells were cultured in αMEM (Minimum Essential medium) supplemented 
with 2% fetal calf serum. After 12 hours, medium was removed and replaced. 
Thirty hours after the first transduction, cells were transduced again as above. 
At 10 and 58 hours, cells were washed three times with PBS and harvested.
RNA extraction. Total RNA was extracted with RNeasy microkit (Qiagen) in-
cluding a DNAse treatment. Extracted RNA was eluted in 15 µl RNase-free 
water. RNA concentration and quality was determined with Experion Au-
tomated Electrophoresis System (BioRad, Marnes-la-Coquette, France) and 
Nanodrop spectrophotometer (Thermo Scientific).
Real time qPCR. First-strand cDNA was prepared using the High capac-
ity reverse transcription kit (Applied Biosystems, Saint Aubin, France) with 
100 ng total RNA and random primers. The expression of osteoblastic tran-
scription factor RUNX2, DLX5, iBSP, and OSTERIX was evaluated by real-time 
quantitative PCR with EvaGreen incorporation (SsoFast EvaGreen kit, CFX96 
Real-time PCR detection system, Biorad). PCR reaction: 4 µl of reverse tran-
scriptase diluted at 2:1 in RNAse-DNAse-free water, 1× SsoFast EvaGreen 
kit, 10 µmol/l of each primer and RNase-free water to a final volume of 10 µl. 
Three minutes preamplification at 95 °C, 40 cycles of 10” at 95 °C and 30” at 
60 °C. The PPIA gene was used as a normalization control.
cDNA microarray analysis. Double-stranded cDNAs were prepared from 
25 ng of total RNA with ovation PicoSL WTA system v2 kit (Nugen Leek, The 
Netherlands). The fragmented end-labeled cDNA was hybridized to Gene-
Chip Human Gene 1.1ST array strip (Affymetrix, High Wycombe, UK) for 20 
hours at 48 °C. After hybridization, the chips were stained and washed in a 
GeneChip Fluidics Station 450 (Affymetrix) and scanned using a GeneChip 
Array scanner (Affymetrix). The raw file generated contained expression in-
tensity data and was used for analysis.
High-throughput studies. Principal component analysis was performed 
for global unsupervised analysis. Supervised analyses for generation of 
each specific gene expression signature were obtained by using of Partek 
Genomics Suite software with the sample-paired t-test that matched each 
donor treatment. Gene expression signature was carried out for fold chang-
es in expression > |1.2|, P < 0.05.
Differentially expressed genes were hierarchically clustered using the TM4 
Microarray Software Suite57 with the Euclidian distance metric and average 
linkage method. Clustering and heatmaps involved TM4 Software Suite. 
Gene expression data with log values < 3 were not considered. Differential 
expression analysis involved a linear model with an empirical Bayes method 
to moderate the standard errors of the estimated log ratio changes. 
ConsensusPathDB-human (http://cpdb.molgen.mpg.de) served for func-
tional annotation analysis with gene ontology terms.58 Venn diagrams were 
obtained with http://bioinformatics.psb.ugent.be. The Gene Set Enrichment 
Analysis59 (GSEA Broad Institute, Cambridge, MA) software was used for ana-
lyzing the median t-test of MS2RLP-RUNX2 or MS2RLP-DLX5 to the IDLV-Luc 
control, with a home-made gene list of osteoblastic markers.
Statistical analysis
Data from three or four independent experiments in triplicate were ana-
lyzed. Data are expressed as mean−SD; Wilcoxon-Mann-Whitney was used 
to analyze the data.
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